Curai Health Collaborates with UMass Chan for COVID-19 Virtual Care Research
In a groundbreaking initiative aimed at enhancing at-home healthcare services, UMass Chan Medical School and Curai Health have teamed up for the NIH-funded "STOP COVID-19" study. This collaborative effort investigates the effectiveness of at-home COVID-19 testing, analyzing at-home antigen and molecular tests in comparison with traditional lab-based PCR tests. The study is particularly timely given the ongoing demand for healthcare solutions amidst the pandemic.
The study encompasses adult participants who will take part in testing for COVID-19 and influenza A/B viruses. Upon receiving a positive test result, these participants will gain access to free virtual care through Curai Health, allowing them to receive necessary medical treatment without the need to leave their homes. This provision aims to streamline the care process for patients feeling unwell, should they test positive for respiratory viruses.
Neal Khosla, CEO of Curai Health, emphasized the urgent need for accessible healthcare services, stating, "The pandemic brought profound changes in all of our expectations for at-home testing and virtual care, and yet there's still a lot of confusion about what you should do if you test positive for COVID-19." Through this partnership, Curai Health intends to furnish patients with quality care and support during their recovery, enabling a more efficient management of health while self-isolating.
The UMass Self-Testing for Our Protection from COVID-19 (STOP COVID-19) study is developed to advance understanding regarding the performance of rapid antigen tests versus PCR tests, particularly post-symptom onset. Over a span of up to 16 weeks, participants will conduct home testing and engage with various health monitoring tools. They will keep track of their health experiences through an app called MyDataHelps, which is supported by Care Evolution, LLC. Additionally, researchers will monitor participants' health data using wearable technology, emphasizing the importance of timely interventions during a health crisis.
Dr. Apurv Soni, an assistant professor of medicine at UMass Chan, stated, "Improving at-home testing for COVID-19 is an important first step, but it needs to be paired with getting clinical care." This highlights the idea that rapid access to clinical support can significantly impact patients' health outcomes, especially those self-isolating and experiencing symptoms associated with COVID-19 or other respiratory viruses. Participants in the study will have the flexibility to obtain care either independently or via immediate access to quality virtual assistance from their homes.
Curai Health leverages advanced machine learning capabilities within its clinical workflows, establishing a comprehensive model of care delivery that ensures continuity for patients over time while remaining cost-effective. Since its inception in 2017, Curai Health's mission has included providing on-demand, high-quality virtual primary and urgent care with the assistance of AI, enhancing the overall patient experience and health outcomes across populations.
This partnership between UMass Chan and Curai Health underscores a dedicated approach to navigating the challenges posed by the pandemic while focusing on the importance of remote healthcare solutions. By merging AI technologies with clinical expertise, they aim to set a new standard in healthcare delivery that prioritizes access, efficiency, and patient-centered care for those affected by COVID-19 and similar health concerns.
The study encompasses adult participants who will take part in testing for COVID-19 and influenza A/B viruses. Upon receiving a positive test result, these participants will gain access to free virtual care through Curai Health, allowing them to receive necessary medical treatment without the need to leave their homes. This provision aims to streamline the care process for patients feeling unwell, should they test positive for respiratory viruses.
Neal Khosla, CEO of Curai Health, emphasized the urgent need for accessible healthcare services, stating, "The pandemic brought profound changes in all of our expectations for at-home testing and virtual care, and yet there's still a lot of confusion about what you should do if you test positive for COVID-19." Through this partnership, Curai Health intends to furnish patients with quality care and support during their recovery, enabling a more efficient management of health while self-isolating.
The UMass Self-Testing for Our Protection from COVID-19 (STOP COVID-19) study is developed to advance understanding regarding the performance of rapid antigen tests versus PCR tests, particularly post-symptom onset. Over a span of up to 16 weeks, participants will conduct home testing and engage with various health monitoring tools. They will keep track of their health experiences through an app called MyDataHelps, which is supported by Care Evolution, LLC. Additionally, researchers will monitor participants' health data using wearable technology, emphasizing the importance of timely interventions during a health crisis.
Dr. Apurv Soni, an assistant professor of medicine at UMass Chan, stated, "Improving at-home testing for COVID-19 is an important first step, but it needs to be paired with getting clinical care." This highlights the idea that rapid access to clinical support can significantly impact patients' health outcomes, especially those self-isolating and experiencing symptoms associated with COVID-19 or other respiratory viruses. Participants in the study will have the flexibility to obtain care either independently or via immediate access to quality virtual assistance from their homes.
Curai Health leverages advanced machine learning capabilities within its clinical workflows, establishing a comprehensive model of care delivery that ensures continuity for patients over time while remaining cost-effective. Since its inception in 2017, Curai Health's mission has included providing on-demand, high-quality virtual primary and urgent care with the assistance of AI, enhancing the overall patient experience and health outcomes across populations.
This partnership between UMass Chan and Curai Health underscores a dedicated approach to navigating the challenges posed by the pandemic while focusing on the importance of remote healthcare solutions. By merging AI technologies with clinical expertise, they aim to set a new standard in healthcare delivery that prioritizes access, efficiency, and patient-centered care for those affected by COVID-19 and similar health concerns.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.